Autres langues Reklaim Ltd.

Actions

MYID

CA7594021007

Marché Fermé - Toronto S.E. Autres places de cotation 19:24:51 15/07/2024			Varia. 5j.	Varia. 1 janv.
0,105 ^CAD	+5,00 %		+5,00 %	+16,67 %

30/05	Reklaim Ltd. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
09/04	Reklaim Ltd. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Reklaim Ltd. Reports Strong Q1 2024 Results: Higher Margins and Increased Cash Flow	31/05
Reklaim Ltd. Reports Strong Q1 2024 Results: Higher Margins and Increased Cash Flow	31/05
Reklaim : Management’s Discussion & Analysis 1Q24	30/05
Reklaim : Interim Financial Statements 1Q24 - Consolidated	30/05
Reklaim : Corporate Presentation	30/05
Reklaim Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	30/05
Reklaim : Corporate Presentation	24/04
Reklaim Cuts Debt by $100,000 Following Warrant Exercise	24/04
Reklaim Ltd. Reduces Debt Following Successful Warrant Exercises	24/04
Reklaim Ltd. Reduces Debt Following Successful Warrant Exercises	24/04
Reklaim Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	09/04
REKLAIM LTD Announces Q4 & 2023 Outcomes: Achieving Profitability with $872K in Profit and a 74% Surge in Annual Revenue	09/04
REKLAIM LTD Announces Q4 & 2023 Outcomes: Achieving Profitability with $872K in Profit and a 74% Surge in Annual Revenue	09/04
Forge Biologics Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is granted UK's Innovation Passport Designation	20/03
Reklaim Expects to Report Profitable Guidance for Fiscal 2023	12/02
Reklaim Ltd Unveils Profitable Guidance for Fiscal 2023	12/02
Reklaim Ltd Unveils Profitable Guidance for Fiscal 2023	12/02
Forge Biologics Announces Positive FBX-101 Clinical Trial Update in Patients with Krabbe Disease Identified by Newborn Screening Ahead of RUSP Vote	30/01
Reklaim Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Reklaim Ltd's Posts Consecutive Profitable Quarters, Q3-2023 Profitability Soars by 107%	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Reklaim Ltd.

Actions

MYID

CA7594021007

Autres langues

Filtres